The Department of Health’s latest guidance, GN-01:2025-1(E), tightens administrative controls for medical device listings in Hong Kong. Manufacturers must now adhere to stricter renewal windows, enhanced Local Responsible Person (LRP) duties, and mandatory tracking for high-risk implants to maintain market access.
Hong Kong, January 5, 2026 – The Medical Device Division (MDD) has released the GN-01:2025-1(E) guidance, updating the Medical Device Administrative Control System (MDACS). While the system remains voluntary pending full legislation, the new framework imposes rigorous lifecycle management obligations on manufacturers and their Local Responsible Persons (LRP). These updates clarify the “cradle-to-grave” responsibilities required to keep devices listed and compliant in the Hong Kong market.
HONG KONG MDACS KEY UPDATES IN GN-01:2025-1(E)
The revised guidance introduces critical changes to the listing and maintenance process, including:
- Stricter Renewal Windows: Renewal applications must be submitted between 12 weeks and 1 year before the listing expiry. Late submissions will be rejected, requiring a full re-application.
- Enhanced LRP Obligations: Local Responsible Persons must now report recalls within 10 calendar days (preferably 4 hours) and serious adverse events within 10 days.
- Patient-Level Tracking: Mandatory tracking systems are required for high-risk Class IV devices (e.g., pacemakers, mechanical heart valves) down to the patient or facility level.
- Surveillance Reporting: Annual surveillance reports must be submitted for specific high-risk devices listed in Appendix 1.
IMPACT ON HONG KONG MDACS MARKET ACCESS
The 2025 update shifts the MDACS from a passive listing system to an active surveillance framework:
- Increased Risk of Delisting: Failure to meet the new post-market surveillance or renewal deadlines can result in immediate removal from the public list.
- Higher Operational Burden: Overseas manufacturers must ensure their LRP is capable of active compliance management, not just administrative filing.
- Preparation for Statutory Control: The guidance explicitly aims to familiarize traders with future mandatory requirements, effectively acting as a “soft launch” for stricter regulation.
HOW COMPANIES CAN COMPLY
To align with the new guidance and avoid market disruption, companies should:
- Audit LRP Agreements: Ensure your designated Local Responsible Person has the resources to handle 24/7 recall reporting and adverse event investigations.
- Update Renewal Calendars: Set alerts for 1 year prior to listing expiry to ensure renewal applications fall within the strict acceptance window.
- Implement Tracking Systems: Verify that patient-level tracking is active for any implantable devices listed in Appendix 1.
- Review Post-Market Protocols: Update standard operating procedures (SOPs) to meet the 10-day reporting deadline for adverse events in Hong Kong.